|
Incanthera PLC on Friday said it has ended an agreement with Limeway Pharma Design Ltd as it focuses on its Skin + Cell skincare range. The Manchester, England-based developer of technologies in dermatology and oncology said it has finished product in stock ready for immediate distribution for its luxury skincare brand Skin + Cell. The firm said it was focusing on monetising the range due to market interest and the short lead time for distribution, ahead of developing its skin solar keratosis treatment and skin melanoma prevention programme called Sol. As a result, Incanthera has terminated the product development and licensing agreement with Limeway Pharma from March 2018. The two companies have agreed to cross licence patent rights on a royalty free basis for future independent work on solar keratosis and skin melanoma. Incanthera said it can continue to develop the Sol project in future. Shares in Incanthera were down 12% to 10.75 pence on the Aquis Exchange on Friday afternoon. Copyright 2025 Alliance News Ltd. All Rights Reserved.
|
